CU20120148A7 - Metodos y composiciones para el suministro intranasal - Google Patents

Metodos y composiciones para el suministro intranasal

Info

Publication number
CU20120148A7
CU20120148A7 CU2012000148A CU20120148A CU20120148A7 CU 20120148 A7 CU20120148 A7 CU 20120148A7 CU 2012000148 A CU2012000148 A CU 2012000148A CU 20120148 A CU20120148 A CU 20120148A CU 20120148 A7 CU20120148 A7 CU 20120148A7
Authority
CU
Cuba
Prior art keywords
methods
compositions
intranasal
supply
powder formulations
Prior art date
Application number
CU2012000148A
Other languages
English (en)
Spanish (es)
Inventor
Ryoichi Nagata
Shunji Haruta
Original Assignee
Shin Nippon Biomedical Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shin Nippon Biomedical Lab filed Critical Shin Nippon Biomedical Lab
Publication of CU20120148A7 publication Critical patent/CU20120148A7/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/05Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/08Clostridium, e.g. Clostridium tetani
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/145Orthomyxoviridae, e.g. influenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • HELECTRICITY
    • H04ELECTRIC COMMUNICATION TECHNIQUE
    • H04MTELEPHONIC COMMUNICATION
    • H04M3/00Automatic or semi-automatic exchanges
    • H04M3/42Systems providing special services or facilities to subscribers
    • H04M3/50Centralised arrangements for answering calls; Centralised arrangements for recording messages for absent or busy subscribers ; Centralised arrangements for recording messages
    • H04M3/51Centralised call answering arrangements requiring operator intervention, e.g. call or contact centers for telemarketing
    • H04M3/5116Centralised call answering arrangements requiring operator intervention, e.g. call or contact centers for telemarketing for emergency applications
    • HELECTRICITY
    • H04ELECTRIC COMMUNICATION TECHNIQUE
    • H04WWIRELESS COMMUNICATION NETWORKS
    • H04W4/00Services specially adapted for wireless communication networks; Facilities therefor
    • H04W4/90Services for handling of emergency or hazardous situations, e.g. earthquake and tsunami warning systems [ETWS]
    • HELECTRICITY
    • H04ELECTRIC COMMUNICATION TECHNIQUE
    • H04WWIRELESS COMMUNICATION NETWORKS
    • H04W76/00Connection management
    • H04W76/50Connection management for emergency connections
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5252Virus inactivated (killed)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • A61K2039/543Mucosal route intranasal
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • HELECTRICITY
    • H04ELECTRIC COMMUNICATION TECHNIQUE
    • H04WWIRELESS COMMUNICATION NETWORKS
    • H04W76/00Connection management
    • H04W76/10Connection setup
    • H04W76/15Setup of multiple wireless link connections
    • HELECTRICITY
    • H04ELECTRIC COMMUNICATION TECHNIQUE
    • H04WWIRELESS COMMUNICATION NETWORKS
    • H04W8/00Network data management
    • H04W8/18Processing of user or subscriber data, e.g. subscribed services, user preferences or user profiles; Transfer of user or subscriber data
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Business, Economics & Management (AREA)
  • Signal Processing (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Emergency Management (AREA)
  • Environmental & Geological Engineering (AREA)
  • Marketing (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CU2012000148A 2010-04-15 2012-10-12 Metodos y composiciones para el suministro intranasal CU20120148A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32454210P 2010-04-15 2010-04-15
PCT/JP2011/002225 WO2011129120A1 (en) 2010-04-15 2011-04-15 Methods and compositions for intranasal delivery

Publications (1)

Publication Number Publication Date
CU20120148A7 true CU20120148A7 (es) 2013-01-30

Family

ID=44798502

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2012000148A CU20120148A7 (es) 2010-04-15 2012-10-12 Metodos y composiciones para el suministro intranasal

Country Status (12)

Country Link
US (2) US9687536B2 (https=)
EP (2) EP2689785B1 (https=)
JP (5) JP5771626B2 (https=)
KR (3) KR102136036B1 (https=)
CN (3) CN102933230B (https=)
BR (1) BR112012026116A2 (https=)
CA (2) CA2796593C (https=)
CU (1) CU20120148A7 (https=)
ES (1) ES2874817T3 (https=)
RU (1) RU2012144612A (https=)
SG (1) SG184304A1 (https=)
WO (1) WO2011129120A1 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102933230B (zh) * 2010-04-15 2016-03-02 株式会社新日本科学 用于鼻内递送的方法和组合物
US9795773B2 (en) 2011-12-16 2017-10-24 Indosys Limited Medicament unit dose cartridge and delivery device
TWI690322B (zh) 2012-10-02 2020-04-11 法商傳斯堅公司 含病毒的調配物及其使用
WO2014186754A2 (en) 2013-05-16 2014-11-20 Board Of Regents The University Of Texas System Dry solid aluminum adjuvant-containing vaccines and related methods thereof
CN104208029B (zh) * 2013-05-30 2017-06-06 上海医药工业研究院 一种鼻用疫苗组合物粉体制剂及其制备方法
RU2720808C2 (ru) * 2013-09-03 2020-05-13 Джорджия Тек Рисёч Корпорейшн Термостабильные препараты вакцин и микроиглы
EP4008307A1 (en) * 2013-09-24 2022-06-08 Satsuma Pharmaceuticals, Inc. Intranasal dhe formulation for the treatment of headache
IL310015B2 (en) 2013-12-31 2026-02-01 Access To Advanced Health Inst Single vial formulation
EP3127550A1 (en) * 2015-08-07 2017-02-08 HSC Development GmbH Stabilizing composition for dry formulation of virus
JP2018533547A (ja) * 2015-09-16 2018-11-15 株式会社新日本科学 ワクチン組成物
GB201610628D0 (en) * 2016-06-17 2016-08-03 Mihranyan Albert New compositions
WO2018053524A1 (en) * 2016-09-19 2018-03-22 Vaxess Technologies, Inc. Vaccine formulations with increased stability
US11022115B2 (en) 2017-06-02 2021-06-01 Purdue Research Foundation Controlled variable delivery external gear machine
JPWO2019021957A1 (ja) * 2017-07-25 2020-07-09 第一三共株式会社 点鼻用乾燥粉末医薬組成物
GB201713899D0 (en) 2017-08-30 2017-10-11 Indosys Ltd Multi-dose medicament delivery device
US11918646B2 (en) 2017-12-11 2024-03-05 Board Of Regents, The University Of Texas System Dry adjuvanted immune stimulating compositions and use thereof for mucosal administration
EP3847246A1 (en) * 2018-09-06 2021-07-14 Bavarian Nordic A/S Storage improved poxvirus compositions
WO2020123607A1 (en) 2018-12-11 2020-06-18 Satsuma Pharmaceuticals, Inc. Compositions, devices, and methods for treating or preventing headaches
JP7660514B2 (ja) * 2019-02-15 2025-04-11 セラム インスティチュート オブ インディア プライベイト リミテッド 弱毒生インフルエンザワクチン組成物及びその調製プロセス
EP3698773A1 (en) 2019-02-21 2020-08-26 Università degli Studi di Parma Composition and manufacturing of powders containing nanoadjuvants for mucosal vaccination
US11621604B2 (en) 2020-02-16 2023-04-04 Purdue Research Foundation Integrated electro-hydraulic machine
CA3175456A1 (en) * 2020-03-24 2021-09-30 Byung Chul Ahn Method of producing serum composition for preventing or treating mucosa-related infectious disease in young mammals, serum composition produced thereby, and use thereof
CN113583970B (zh) * 2021-07-29 2023-05-12 吉林大学 一种用于预防或抗冠状病毒传播、致病的药物及其制备方法
CN119866231A (zh) 2022-09-01 2025-04-22 锡拉坎岛有限公司 干粉药物递送装置
EP4630460A1 (en) * 2022-12-07 2025-10-15 Daocheng Zhu Formulation and use of a fusion protein
WO2024228212A1 (en) * 2023-05-01 2024-11-07 Biovet Private Limited Bio-lumpivaxin formulations and method of preparation thereof
WO2024246607A1 (en) * 2023-05-31 2024-12-05 Shin Nippon Biomedical Laboratories, Ltd. Compositions for enhanced mucosal penetration
GB202403611D0 (en) 2024-03-13 2024-04-24 Therakind Ltd Improved multi-dose medicament delivery device
CN118924744A (zh) * 2024-07-29 2024-11-12 复旦大学 小分子抑制剂ha15在抗乙型肝炎病毒中的应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5547594A (en) * 1992-11-03 1994-05-24 Secretech, Inc. Microcrystalline cellulose as an immune adjuvant
US20030092145A1 (en) 2000-08-24 2003-05-15 Vic Jira Viral vaccine composition, process, and methods of use
CN1193745C (zh) 2001-02-27 2005-03-23 国家医药管理局上海医药工业研究院 一种鼻用鲑降钙素粉末吸入剂及制备方法
CN1607941A (zh) 2001-11-19 2005-04-20 贝克顿迪肯森公司 粒状药物组合物
WO2003086443A1 (en) 2002-04-11 2003-10-23 Medimmune Vaccines, Inc. Spray freeze dry of compositions for intranasal administration
EP1701738B1 (en) * 2003-12-17 2015-03-11 Wyeth LLC Method for producing storage stable RSV compositions
US20060292173A1 (en) 2004-12-13 2006-12-28 Macadam Donald H Multibacterial vaccines and uses thereof
PT1954308E (pt) 2005-09-16 2011-11-03 Merial Ltd Estabilizadores para vacinas liofilizadas
BRPI0616879A2 (pt) 2005-10-04 2011-07-05 Alk Abello As formulação de vacina sólida
EP1933867A1 (en) 2005-10-04 2008-06-25 Alk-Abello A/S Solid vaccine formulation
AU2007215080A1 (en) 2006-02-13 2007-08-23 Fraunhofer Usa, Inc. Influenza antigens, vaccine compositions, and related methods
EP2004226A1 (en) 2006-03-24 2008-12-24 Novartis Vaccines and Diagnostics GmbH & Co. KG Storage of influenza vaccines without refrigeration
ITMI20061117A1 (it) 2006-06-09 2007-12-10 Michele Bonanomi Una composizione farmaceutica per la somministrazione sublinguale di vaccini metodo per la sua preparazione e sui usi
US20080226729A1 (en) 2006-09-08 2008-09-18 Becton, Dickinson And Company Stable powder formulations of alum-adsorbed vaccines
SG10202012986SA (en) * 2006-09-29 2021-01-28 Ligocyte Pharmaceuticals Inc Norovirus vaccine formulations
CN101668544B (zh) * 2006-12-26 2013-04-24 株式会社新日本科学 经鼻投用制剂
CA2681567C (en) * 2007-03-22 2016-07-19 The Regents Of The University Of Colorado, A Body Corporate Method of preparing an immunologically-active adjuvant-bound dried vaccine composition
WO2009006299A2 (en) 2007-06-29 2009-01-08 Dr. Reddy's Laboratories Ltd. Multi-particulate systems
ES2615390T3 (es) * 2008-03-05 2017-06-06 Sanofi Pasteur Proceso para estabilizar una composición de vacuna que contiene adyuvante
CN101601860A (zh) * 2008-06-13 2009-12-16 中国科学院过程工程研究所 疫苗
MY172788A (en) 2008-08-01 2019-12-12 Gamma Vaccines Pty Ltd Influenza vaccines
US9101539B2 (en) * 2009-05-15 2015-08-11 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical compositions with improved pharmacokinetics
GB2472327B (en) * 2009-07-31 2013-03-13 Shin Nippon Biomedical Lab Ltd Intranasal granisetron and nasal applicator
JP5491119B2 (ja) 2009-10-02 2014-05-14 日東電工株式会社 薬物含有微粒子を含む医薬組成物およびその製造方法
AU2012244074B2 (en) 2010-04-15 2015-01-15 Km Biologics Co., Ltd. Methods and compositions for intranasal delivery
CN102933230B (zh) 2010-04-15 2016-03-02 株式会社新日本科学 用于鼻内递送的方法和组合物

Also Published As

Publication number Publication date
JP6827488B2 (ja) 2021-02-10
JP2013126989A (ja) 2013-06-27
US20130273120A1 (en) 2013-10-17
KR20130083376A (ko) 2013-07-22
EP2689785B1 (en) 2021-05-19
CN103126996A (zh) 2013-06-05
JP2019104751A (ja) 2019-06-27
SG184304A1 (en) 2012-11-29
US9687536B2 (en) 2017-06-27
RU2012144612A (ru) 2014-05-20
BR112012026116A2 (pt) 2016-06-28
JP5771626B2 (ja) 2015-09-02
CN107260689A (zh) 2017-10-20
KR102136036B1 (ko) 2020-07-20
CN102933230B (zh) 2016-03-02
CA2993242A1 (en) 2011-10-20
CN102933230A (zh) 2013-02-13
US20130129781A1 (en) 2013-05-23
WO2011129120A1 (en) 2011-10-20
CA2993242C (en) 2020-12-15
EP2558120A1 (en) 2013-02-20
KR101960102B1 (ko) 2019-03-19
JP2016006119A (ja) 2016-01-14
CA2796593C (en) 2020-12-15
JP2017186377A (ja) 2017-10-12
JP2013523602A (ja) 2013-06-17
CA2796593A1 (en) 2011-10-20
KR20130064741A (ko) 2013-06-18
EP2689785A1 (en) 2014-01-29
EP2558120A4 (en) 2013-08-28
KR20190028555A (ko) 2019-03-18
US10463723B2 (en) 2019-11-05
ES2874817T3 (es) 2021-11-05

Similar Documents

Publication Publication Date Title
CU20120148A7 (es) Metodos y composiciones para el suministro intranasal
CY1120790T1 (el) Συνθεσεις mrna toy cftr και σχετιζομενες μεθοδοι και χρησεις
PT3061454T (pt) Composições veterinárias orais parasiticidas compreendendo agentes activos de actuação sistémica, métodos e as suas utilizações
CO6771417A2 (es) Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis
UY34333A (es) ?métodos y composiciones para el control de malezas, y métodos para reducir la expresión de enzima dhps?
EA201490381A1 (ru) Синтетические наноносители, которые стимулируют формирование гуморального иммунного ответа и иммунного ответа, опосредованного цитотоксическими т-лимфоцитами (ctl)
DOP2016000287A (es) Composiciones y métodos para modular la expresión de ttr y vh
MX2012008717A (es) Composiciones para el cuidado oral.
CO6801729A2 (es) Composiciones y métodos para modular el fxr
PE20150627A1 (es) Derivados de c17-alcandiilo y alquendiilo del acido oleanolico y sus metodos de uso
AR081681A1 (es) METODOS Y COMPOSICIONES PARA LA ADMINISTRACION INTRATECAL DE b-GALACTOCEREBROSIDASA
CO7240373A2 (es) Formulaciones proliposomales de testosterona
ECSP18010481A (es) Composiciones de plinabulina
UY34406A (es) Compuestos y métodos para mejorar la respuesta inmune innata
CO7151511A2 (es) Derivado de cicloalcano
CO7350620A2 (es) Nuevos derivados de piridina
CY1117209T1 (el) Συνθεσεις περιλαμβανοντας 15-ηερε και μεθοδοι χρησης των ιδιων
CR20130521S (es) Aparato para peinar el cabello
PH12017500836A1 (en) Transdermal formulations
UA115357C2 (uk) Похідні піридин-4-ілу
WO2013177444A3 (en) Influenza vaccine constructs
EA201170294A1 (ru) Способы лечения реперфузионных повреждений
CY1116004T1 (el) Παραγωγα οξαζολυλ-μεθυλαιθερα ως αγωνιστες υποδοχεα alx
UY33794A (es) Inhibidores diméricos de las iap
UY33812A (es) Generador Eólico Sincrónico